Penguin Solutions Completes Redomiciliation to the United States
The redomiciliation was completed following the close of trading on June 30, 2025. At completion, all issued ordinary shares and preferred shares of Penguin Solutions, Inc., a Cayman Islands exempted company ('Penguin Solutions Cayman'), were exchanged on a one-for-one basis for newly issued shares of common stock and shares of preferred stock, respectively, of the Company. The former shareholders of Penguin Solutions Cayman are now the stockholders of the Company, which is the parent company of the Penguin Solutions group of companies. The common stock of the Company will begin trading on the Nasdaq Global Select Market on July 1, 2025, with its trading symbol of 'PENG' remaining unchanged.
The Company does not anticipate any material impact to its employees or its day-to-day business as a result of the completion of the redomiciliation.
For more information on the redomiciliation of the Company, please refer to a copy of the Sanction Order issued by the Grand Court of the Cayman Islands which approved the redomiciliation, available under the Governance section of our Investor Relations website.
About Penguin Solutions
The most exciting technological advancements are also the most challenging for companies to adopt. At Penguin Solutions, we support our customers in achieving their ambitions across our Advanced Computing, Integrated Memory, and Optimized LED business segments. With our expert skills, experience, and partnerships, we turn our customers' most complex challenges into compelling opportunities.
For more information, visit https://www.penguinsolutions.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
Barclays bullish on Kimco, Federal Realty as it launches coverage of retail REITs
-- Barclays starts coverage of retail REITs, rating Kimco Realty (NYSE:KIM) and Federal Realty Investment Trust (NYSE:FRT) Overweight while it was Equal weight on Regency Centers (NASDAQ:REG), Phillips Edison, Simon Property Group (NYSE:SPG) and Tanger. The brokerage said investors appear to be overpaying for the perceived defensiveness of certain grocery‑anchored portfolios, yet Kimco itself offers a cheaper way to own that theme. Barclays said New York‑based landlord is a large cap, high‑quality, diversified 'proxy' for grocery‑anchored shopping centers, trading at a modest discount to peers and set for about 5% funds‑from‑operations (FFO) growth next year. Federal Realty, whose high‑end shopping districts span U.S. coastal markets, has lagged rivals since the pandemic but is shifting capital toward lower‑risk acquisitions and more modest redevelopments, the note said. While Regency, Phillips Edison, Simon and Tanger all look fairly valued, the broker wrote. Regency carries a three‑turn premium to the sector on forward FFO, Phillips Edison still trades above peers despite shrinking returns on recent acquisitions, and both Simon and Tanger face apparel‑heavy tenant rosters that could be squeezed further if tariffs rise. Barclays' sector outlook favours companies with strong balance sheets and improving free‑cash‑flow profiles, and is wary of REITs chasing FFO growth through acquisitions after a sharp compression in shopping‑center cap rates. While consumer spending and tariff risks loom, Kimco and Federal Realty still screen as the best risk‑reward ideas in a retail landscape adjusting to slower economic growth. Investors, the bank cautioned, should remember that 'investors may be overpaying for the perceived defensiveness of certain grocery‑anchored portfolios.' Related articles Barclays bullish on Kimco, Federal Realty as it launches coverage of retail REITs Roblox: What's behind the meteoric rise of 'Grow a Garden' Quantum Computing started at Neutral on steep valuation, slow commercialization Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
33 minutes ago
- Yahoo
Got $200? 2 Biotech Stocks to Buy and Hold Forever
Good news for investors: You don't have to start out with tons of cash to grow wealth. Biotech stocks offer you a great opportunity to get in on innovators that may produce major growth down the road. 10 stocks we like better than Viking Therapeutics › Some potential investors hesitate to get started on building an investment portfolio because they think they need thousands of dollars to grow wealth. But I've got good news for them and for you: You don't have to start out with a huge pile of cash to invest in stocks that may significantly add value to your portfolio over time. In fact, with just $200, you can get in on players that could help you along the path to wealth. The industry of biotech is a great place to look for such stocks since so many of these companies are developing cutting-edge technologies that may lead to high-growth products, and revenue, down the road. Let's consider two that you might buy today -- a few shares of each for a total of $200 -- and hold forever to benefit from lasting growth stories. Viking Therapeutics (NASDAQ: VKTX) aims to make its mark in one of today's (and tomorrow's) biggest healthcare growth areas: weight loss drugs. The biotech company is developing a dual GIP/GLP-1 receptor agonist, known as VK2735, and has progressed into late-stage clinical trials. The candidate, in injectable form, just launched its phase 3 program and aims to enroll more than 4,000 participants with obesity and more than 1,000 volunteers with obesity and type 2 diabetes. VK2735 works by interacting with hormonal pathways involved in the control of appetite and blood sugar levels, much like the already commercialized Mounjaro and Zepbound, sold by Eli Lilly, and Ozempic and Wegovy, sold by Novo Nordisk. But the fact that similar drugs have reached the market first doesn't mean Viking can't succeed here. Demand for these sorts of products has been so high that it exceeded supply, until Lilly and Novo Nordisk increased manufacturing capacity. So there's plenty of room for a young company like Viking to succeed here too if all continues to go well in clinical trials. Viking also is testing VK2735 in oral form in a phase 2 trial, an important point since oral formulation could make these drugs easier to take, and it involves faster and cheaper manufacturing processes for the company. Data from that trial is expected later this year. Viking stock is known to soar on positive results. It surged more than 120% last year in just one trading session after reporting positive phase 2 data for VK2735. It's since given up the gains, offering investors a solid entry point, but any good news and a possible regulatory nod could prompt the stock to skyrocket. Moderna (NASDAQ: MRNA) used to be a favorite of investors during the early days of the coronavirus pandemic -- but since, it's had trouble bringing investors back into its potential growth story. The stock has lost more than 90% since its peak back in 2021, and the company has reported decreasing sales because of the drop in demand for its coronavirus vaccine and lower-than-expected sales of its more recently launched respiratory syncytial virus (RSV) vaccine. After Moderna's billions of dollars in revenue and profit just a couple of years ago and recent earnings declines, investors may find it difficult to get excited about Moderna again. But it's important to remember two things: First, it's unfair to compare revenue potential during ordinary times to revenue linked to a pandemic-related product. Those were exceptional times that don't occur often. Second, the approval of Moderna's coronavirus and RSV vaccines show that its technology -- the technology driving the rest of its pipeline -- works. The company now has many late-stage products in the works and aims to launch as many as 10 over the next few years. If Moderna even makes it partially to that goal, its revenue picture a few years from now may look very different from the picture today -- and set the company up for long-term growth. It's too early to predict when the market will recognize this and flock to Moderna shares. But at today's level, the stock offers investors a buying opportunity, making it a great place to park part of your $200 and hold on for the long-term as this growth story develops. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 30, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool recommends Moderna, Novo Nordisk, and Viking Therapeutics. The Motley Fool has a disclosure policy. Got $200? 2 Biotech Stocks to Buy and Hold Forever was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
42 minutes ago
- Yahoo
Boeing (NYSE:BA) Advances Space Connectivity And Strengthens Defense Leadership With New CEO
Boeing has recently seen significant events that align with a 24% price increase over the last quarter. The company completed the delivery of O3b mPOWER satellites, enhancing its connectivity solutions, and appointed Stephen Parker as president and CEO of its Defense, Space & Security division, which showed operational recovery. In the broader market, indices like the S&P 500 and Nasdaq have also seen upbeat performance, with a rise of 14% over the year. These developments likely provided additional momentum to Boeing's price movements, amidst an overall positive market trend. You should learn about the 3 risks we've spotted with Boeing (including 1 which is potentially serious). Find companies with promising cash flow potential yet trading below their fair value. The recent developments at Boeing, including the delivery of O3b mPOWER satellites and the appointment of Stephen Parker, hold significant implications for the company's strategic path. These events may bolster Boeing's growth narrative by potentially stabilizing production rates for its commercial jets, while also strengthening its position in the defense sector through leadership changes. These moves could increase investor confidence in Boeing's capacity for revenue recovery amidst ongoing challenges in tariffs, supply chains, and certification delays. In the past three years, Boeing's total shareholder return has been 52.35%. This context highlights a robust long-term performance relative to recent market movements. Over the past year, however, Boeing underperformed the US Aerospace & Defense industry, which achieved a return of 43.8%. Yet, it matched the US market return of 13.9% in the same period, illustrating a complex performance landscape. The impact of recent news on Boeing's revenue and earnings forecasts is likely positive. Increased production rates promise a stronger revenue stream supported by a substantial backlog. Additionally, the divestiture of Digital Aviation Solutions is expected to enhance cash flows, potentially reducing the negative earnings of US$11.65 billion. Furthermore, winning the F-47 fighter jet contract could provide a stable revenue flow in the defense division. Despite a 24% quarterly share price increase, Boeing's current price of US$200.26 is still below the consensus analyst price target of US$219.47, with an 8.8% growth potential implied by this target. Analysts' expectations for revenue of US$111.8 billion and earnings of US$6.5 billion by 2028 underline a belief in Boeing's recovery trajectory, albeit amid varying analyst projections and market uncertainties. Take a closer look at Boeing's potential here in our financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:BA. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
